You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 153 No. 8, August 1999 TABLE OF CONTENTS
  Archives
  •  Online Features
  Article
 This Article
 •Full text
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (8)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Lipid Intolerance in Neonates Receiving Dexamethasone for Bronchopulmonary Dysplasia

Sanjiv B. Amin, MD; Robert A. Sinkin, MD; Michael P. McDermott, PhD; James W. Kendig, MD

Arch Pediatr Adolesc Med. 1999;153:795-800.

Background  We hypothesized that dexamethasone induces hypertriglyceridemia (triglyceride levels >2.82 mmol/L [250 mg/dL]) and increases free fatty acid (FFA) levels and that steroid-induced hypertriglyceridemia is associated with hyperinsulinemia and elevated FFA levels.

Objective  To study the effect of dexamethasone sodium phosphate on lipid metabolism in neonates receiving intravenous lipids.

Design  A prospective cohort study with patients serving as their own controls.

Setting  Neonatal Intensive Care Unit, Children's Hospital at Strong, Rochester, NY.

Methods  All neonates younger than 29 weeks' gestational age at birth receiving 3 g/kg per day of intravenous lipids who were to start dexamethasone therapy for bronchopulmonary dysplasia were eligible. Exclusion criteria included neonates with active infection, prior hypertriglyceridemia, bleeding manifestations, recent surgery, thyroid medication, and human recombinant insulin intravenous infusion therapy. Ten neonates were studied. Blood was drawn for triglyceride, FFA, and insulin assays before initiating and at 1, 2, 3, and 5 days after starting dexamethasone therapy. On day 3, dexamethasone dosage was decreased as per protocol. Intravenous lipid intake was kept constant. Statistical analysis was done using a paired t test.

Results  Six of 10 neonates reached a state of hypertriglyceridemia (95% confidence interval, 26.2%-87.8%). The mean average increase in triglycerides, insulin, and FFA levels in neonates receiving 3 g/kg per day of intravenous lipids after initiation of dexamethasone therapy was 0.75 mmol/L (66.6 mg/dL) (P=.007), 127 pmol/L (P=.006), and 47.5 µmol/L (P=.65), respectively. Six neonates who developed hypertriglyceridemia had significantly elevated mean peak FFA levels (918.3 µmol/L) prior to developing hypertriglyceridemia compared with 4 neonates (mean peak FFA levels, 380.2 µmol/L) who had triglyceride levels lower than 2.82 mmol/L (250 mg/dL) (P=.002).

Conclusion  We conclude that dexamethasone induces hypertriglyceridemia in the presence of hyperinsulinemia and increased FFA levels.


From the Department of Pediatrics, Division of Neonatology, Children's Hospital at Strong, University of Rochester School of Medicine and Dentistry, Rochester, NY.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Enhancing Parenteral Nutrition Therapy for the Neonate
Valentine and Puthoff
Nutr Clin Pract 2007;22:183-193.
ABSTRACT | FULL TEXT  

Prospective Evaluation of Postnatal Steroid Administration: A 1-Year Experience From the California Perinatal Quality Care Collaborative
Finer et al.
Pediatrics 2006;117:704-713.
ABSTRACT | FULL TEXT  

Dexamethasone treatment in the newborn rat: fatty acid profiling of lung, brain, and serum lipids
Bruder et al.
J. Appl. Physiol. 2005;98:981-990.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.